On October 2, 2023, BGI Genomics signed a Memorandum of Understanding (MoU) with the Colombian National Cancer Institute (INC or Instituto Nacional de Cancerologia). This collaboration, which aims to foster research and further develop cutting-edge solutions based on genetic sequencing for early diagnosis of cervical and colorectal cancer, reflects a shared dedication to enhancing health outcomes in the region.

From left to right: BGI Genomics Colombia Rainer Perez & Marco Antonio Rincón, National Cancer Institute Dr. Carolina Wiesner, Dr. Alba Lucia Combita & Dr. Alvaro Acosta.

The MoU was formally inked at INC facilities by Dr. Carolina Wiesner, INC Director, and Mr. Rainer Perez, alternate legal representative of BGI Genomics in Colombia. Mr. Marco Antonio Rincón, Colombia Business Director, BGI Genomics, notes: "BGI Genomics is 100 percent committed to providing cost-effective tools for the prevention and management of Human papillomavirus (HPV) and colorectal cancer to make a meaningful impact on the healthcare of Colombian people." As part of this MoU, BGI Genomics will also train INC personnel.

National Cancer Institute Director Dr. Wiesner and BGI Genomics Rainer Perez signing the MoU

The Colombian National Cancer Institute was created in 1934, and for over seven decades the INC has been committed to the provision of a comprehensive approach to prevention, treatment, rehabilitation and research of cancer in the Colombian population.

Earlier, on September 26, 2023, Mr. Rincón took part as a panelist on behalf of BGI Genomics at the Health and Innovation Event during the 8th China-Colombia Dialogue Conference, held in Bogota, Colombia.

From left to right: Leandro Ramos (Sinopharm), Marco Antonio Rincón, Diana Calderon (Sinovac), Dr. Hernando Pombo and Colombian Health Ministry Advisor Dr. Carolina Gómez

This event, organized by the Colombian Chinese Chamber of Investment & Commerce and the Embassy of the People's Republic of China in Colombia, provided a platform for thought leaders to discuss critical healthcare issues. Dr. Carolina Gómez, Manager at Bogotá Bio and Colombian Health Ministry Advisor, moderated a panel where Mr. Rincón highlighted BGI Genomics' commitment to strengthening local human capital and talent with every local project. He also emphasized that the company seeks to promote access to innovative solutions, precision medicine and cost-effective technologies for the country's health system.

About BGI Genomics:

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

Read more:

Cancel Cervical Cancer – In Conversation with Brazil, Colombia, and Uruguay Experts | BGI Insight

Addressing Barriers to Cervical Cancer Screening in Uruguay | BGI Insight

Empowering Precision Medicine in Argentina, Brazil and Chile - BGI Updates